Related Experiment Video

Updated: Nov 20, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K

Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure

Manabu Taneike1,2, Makoto Nishida1,2, Kaori Nakanishi1

  • 1Health and Counseling Center, Osaka University, 1-17 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.

Scientific Reports
|January 22, 2021
PubMed

Insights

Soluble alpha-Klotho (sαKl) levels increase in heart failure patients and may predict treatment response. Higher sαKl on admission indicates better outcomes, particularly in males, suggesting its potential as a personalized therapy biomarker.

Area of Science:

  • Cardiology
  • Endocrinology
  • Geriatrics

Background:

  • Heart failure is a leading cause of mortality, especially in the elderly.
  • Soluble alpha-Klotho (sαKl) is implicated in various diseases, but its role in heart failure is unclear.
  • Investigating sαKl in heart failure could reveal new diagnostic and therapeutic insights.

Purpose of the Study:

  • To determine sαKl levels in heart failure patients.
  • To explore the association between sαKl and treatment responsiveness.
  • To examine potential sex-based differences in sαKl levels and heart failure outcomes.

Main Methods:

  • Analysis of 28 acute heart failure patients (NYHA score 3.3, LVEF 17.0%, BNP 588 pg/mL).
  • Measurement of sαKl levels on admission.
  • Comparison of sαKl levels between patients who improved and those who did not after treatment.

Main Results:

  • sαKl levels were significantly elevated in heart failure patients.
  • Higher admission sαKl levels correlated with better treatment improvement.
  • sαKl levels decreased in patients who showed improvement.
  • sαKl levels increased in male, but not female, heart failure patients.

Conclusions:

  • sαKl may serve as a novel biomarker for predicting treatment responsiveness in heart failure with reduced ejection fraction.
  • Findings suggest potential for personalized heart failure therapy based on sαKl levels.
  • Further research is warranted to elucidate the precise role and mechanisms of sαKl in heart failure.

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

398
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
108
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
92
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
612
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
230
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
151
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671